The Efficacy and Effectiveness in HBA1C-Lowering is Dependent on Baseline Body Mass Index (BMI) for Sitagliptin but not Canagliflozin in the Treatment of Type 2 Diabetes Mellitus (T2DM)
Nov 1, 2014, 00:00
10.1016/j.jval.2014.08.639
https://www.valueinhealthjournal.com/article/S1098-3015(14)02569-8/fulltext
Title :
The Efficacy and Effectiveness in HBA1C-Lowering is Dependent on Baseline Body Mass Index (BMI) for Sitagliptin but not Canagliflozin in the Treatment of Type 2 Diabetes Mellitus (T2DM)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(14)02569-8&doi=10.1016/j.jval.2014.08.639
First page :
A334
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
60